Evidence map›Paper›PMID 32589297›Full record

ArticleThe International journal of pharmacy practice2020

Community pharmacy: a crucial enabler in creating the effectiveness study environment in the Salford Lung Studies.

David A Leather, Steve Howard, Gerry Haydock, Linda Stephens

Open access · hybridAbstract read
In one paragraph

Article in The International journal of pharmacy practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

David A LeatherGlobal Respiratory Franchise, GlaxoSmithKline plc., Brentford, Middlesex, UK.ORCID https://orcid.org/0000-0002-5871-0975
Steve HowardMcKesson UK, Coventry, UK.
Gerry HaydockPCT Healthcare Ltd, Manchester, UK.
Linda StephensGlobal Respiratory Franchise, GlaxoSmithKline plc., Brentford, Middlesex, UK.
GlaxoSmithKline (United Kingdom) · GBCoventry (United Kingdom) · GB

Funding

GlaxoSmithKline plc.
6 · The paper itself

Abstract

objectiveCreating an environment that supports conditions of routine clinical practice and enables an effectiveness trial design with a pre-licensed medicine is extremely challenging. Here, we summarise our experiences and achievements with engaging and mobilising community pharmacies in and around Salford, United Kingdom, in the Phase III effectiveness Salford Lung Studies (SLS).

methodsThis article provides the authors' personal experiences and viewpoints on community pharmacy involvement in the SLS. KEY

findingsMore than 130 community pharmacies were enabled, and >2500 pharmacy staff trained, for involvement in the SLS. Key to community pharmacy participation in the SLS was the formation of the SLS Pharmacy Steering Group (PSG), contributing to study oversight, and the development of a pharmacy standard operating procedure document, the major principle of which was to ensure minimum disruption to the normal medicine dispensing process while ensuring compliance with regulations, guidelines, good clinical practice and requirements for pharmacovigilance. The high level of commitment and collaboration of community pharmacy in the SLS demonstrated a willingness to work together and take on additional and novel roles beyond their everyday commercial functions for the benefit of patients, despite normally competing for prescription business.

conclusionsThe involvement and integration of community pharmacy as a key partner in the SLS was pivotal in securing the delivery of these world-first clinical effectiveness studies. To our knowledge, this has not been previously achieved in a study of a pre-licensed maintenance therapy for a common disease in primary care.

Indexed as

Research DesignAndrostadienesAsthmaBenzyl AlcoholsChlorobenzenesClinical Trials, Phase III as TopicCommunity Pharmacy ServicesDrug CombinationsDrugs, InvestigationalGeneral PractitionersHumansIntersectoral CollaborationPharmacistsPragmatic Clinical Trials as TopicPrimary Health CarePulmonary Disease, Chronic ObstructiveAndrostadienesBenzyl AlcoholsChlorobenzenesDrug CombinationsDrugs, Investigationalfluticasone furoate-vilanterol trifenatateClinical PracticCommunity PharmacyEffectiveness TrialPrimary CareSalford Lung Studies

Identifiers

PMID32589297
PMCPMC7586830
OpenAlexW3038009716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.